Sign in
TerminatedNo phase

Watchful Waiting for Complete Responders to Therapy in Rectal Cancer

Key facts

Who runs it
Henry Ford Health System
Where
Detroit, United StatesSee the site
Trial code
Status
Terminated
People taking part
15 people enrolled
Started
10 Jul 2018
Ended
31 Mar 2026
Type of study
Interventional
Treatments tested
  • Watchfuf waiting
Record updated
23 July 2026
Why it stopped
Lack of financial support

Who can take part

Age
18 years to 95 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Age ≥ 18 years
  • Diagnosis of rectal invasive adenocarcinoma
  • Tumor in the low rectum lying < 4 cm from the anal verge
  • Clinical stage T3/N0-N1M0
  • Patients with low T2 who will need abdominal perineal resection are also eligible

Who cannot take part

  • Other forms of cancer
  • Age less than 18 years
  • Tumors >= 4 cm from the anal verge
  • Tumors of other clinical stages than listed above

Where in United States

  • Ascension St. John HospitalDetroit, United States

About the trial

What the trial wants to find out

The purpose of this project is to determine if in a selected group of patients, at higher risk of wound dehiscence and other complications, treatment by local excision and management by a "watchful waiting" or an initial "non-operative management" approach, with an offer of radical resection only to those patients whose tumors demonstrate "regrowth" will maintain acceptable local control and overall survival rate for the whole cohort.

The group in the trial

  • Watchful WaitingTreatment being tested

    Six cycles of FOLFOX (infusional fluorouracil, leucovorin, and oxaliplatin) will be administered every two weeks according to protocol. After a 3 week recovery period, this will be followed by conventional concurrent radiation and 5FU/capecitabine. Patients will be re-staged two to three weeks after completion of induction FOLFOX therapy to ensure no disease progression. The patients will be re-staged again at least 7-11 weeks post completion of nCRT. Patients with restaging results showing either complete or near complete response, will be allocated to "watchful waiting."

    Treatment: Watchfuf waiting

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Treatment of T2-T3/NO-N+ Adenocarcinoma of the Rectum by Neoadjuvant Chemotherapy (FOLFOX) Followed by Preoperative Chemo (Fluorouracil / Capecitabine)-Radio Therapy (CRT) With Watchful Waiting for Complete Responders
Record updated
23 July 2026